Assessment of real-world treatment patterns and outcomes of olutasidenib in patients with mutated isocitrate dehydrogenase 1 Acute Myeloid Leukemia previously treated with venetoclax using electronic health record data
Catherine Lai(University of Pennsylvania), Aaron Sheppard(Sunesis (United States)), Amber Thomassen(Rigel (United States)), Thomas P. Leahy(Systems, Applications & Products in Data Processing (Canada)), Timothy Werwath, Yasmin Abaza(Northwestern University), Pinkal Desai(NewYork–Presbyterian Hospital), Jörge E. Cortes(Augusta University Health)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621